PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833409
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833409
Anorexiants Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Anorexiants Market was valued at USD 1.07 billion in 2024 and is estimated to grow at a CAGR of 5.2% to reach USD 1.75 billion by 2034.
The global rise in obesity and overweight populations is one of the primary drivers of the anorexiants market. As lifestyle diseases like type 2 diabetes, hypertension, and cardiovascular diseases become more prevalent, demand for weight management drugs, including anorexiants, continues to grow.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $1.07 Billion |
| Forecast Value | $1.75 Billion |
| CAGR | 5.2% |
Rising Adoption of CNS Stimulants
The CNS stimulants segment generated significant revenues in 2024, driven by appetite suppression and weight management. Medications in this category, like phentermine and diethylpropion, work by increasing dopamine and norepinephrine levels in the brain, which suppresses appetite and promotes energy expenditure. This segment is expected to witness continued growth, particularly in the prescription weight loss space, as more patients turn to medications that can help them manage obesity and related conditions like type 2 diabetes.
Oral to Gain Traction
The oral segment of the anorexiants market held a substantial share in 2024, driven by patient preference for easy-to-use, non-invasive treatments. Oral anorexiants like Orlistat and phentermine/topiramate have become popular choices due to their convenience, availability, and proven efficacy. These drugs are often prescribed as part of a broader weight management regimen that includes dietary changes and physical activity.
Increasing Prevalence of Obesity
The obesity segment held a robust share in 2024, driven by the escalating global obesity crisis. With increasing rates of obesity linked to chronic diseases like hypertension, type 2 diabetes, and cardiovascular diseases, demand for effective weight-loss therapies is surging. Anorexiants in this segment are viewed as critical tools in the management of moderate to severe obesity, especially when lifestyle changes like diet and exercise alone are insufficient.
North America to Emerge as a Lucrative Region
North America anorexiants market will grow at a decent CAGR during 2025-2034, owing to well-established healthcare infrastructure, high levels of healthcare spending, and increasing awareness about obesity-related health risks. As a result, North American companies are focusing on launching new anorexiants and leveraging direct-to-consumer marketing strategies to increase drug adoption.
Major players in the anorexiants market are KVK-Tech, Teva Pharmaceuticals, Lannett Company, Novo Nordisk, Valeant Pharmaceuticals, Currax Pharmaceuticals, Eli Lilly and Company, Aventis Pharmaceuticals, Zydus Pharmaceuticals, Pfizer, and Vivus.
To strengthen their presence and market foothold, companies in the anorexiants market are employing a variety of key strategies. These include innovative product development, particularly regarding combination therapies and non-stimulant formulations, which cater to different patient preferences and needs. Companies are also investing heavily in patient education and digital health solutions, such as apps and online counseling services, to increase treatment adherence and optimize weight loss outcomes.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumption and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional
- 2.2.2 Drug class
- 2.2.3 Route of administration
- 2.2.4 Indication
- 2.2.5 Drug Type
- 2.2.6 Distribution channel
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of obesity and metabolic disorders
- 3.2.1.2 Growing geriatric and adolescent populations
- 3.2.1.3 Enhanced clinical awareness and treatment guidelines
- 3.2.1.4 Expansion of digital health and telemedicine platforms
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of branded and biologic therapies
- 3.2.2.2 Safety concerns and side effects
- 3.2.3 Market opportunities
- 3.2.3.1 Rising demand in emerging markets
- 3.2.3.2 Growing shift toward personalized and combination therapies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Future market trends
- 3.6 Clinical trial analysis
- 3.7 Pricing analysis
- 3.8 Technology and innovation landscape
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 GLP-1 receptor agonists
- 5.3 CNS stimulants
- 5.4 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Obesity
- 7.3 Overweight with comorbidities
Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Branded
- 8.3 Generics
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 Retail pharmacies
- 9.3 Hospital pharmacies
- 9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
Chapter 11 Company Profiles
- 11.1 Aventis Pharmaceuticals
- 11.2 Currax Pharmaceuticals
- 11.3 Eli Lilly
- 11.4 KVK-Tech
- 11.5 Lannett Company
- 11.6 Novo Nordisk
- 11.7 Pfizer
- 11.8 Teva Pharmaceuticals
- 11.9 Valeant Pharmaceuticals
- 11.10 Vivus
- 11.11 Zydus Pharmaceuticals
